Congresses and Publications

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101

Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

BGB-16673, a BTK degrader, in patients with R/R CLL/SLL: Preliminary phase 1 results from CaDAnCe-101 Extended follow-up of zanubrutinib-treated patients with Waldenström macroglobulinemia from the ASPEN trial through LTE1 Proposed standard of care for active monitoring in Waldenström macroglobulinemia from a UK-wide patient-expert collaboration Sonrotoclax + zanubrutinib for TN-CLL demonstrates MRD clearance and tolerability in ongoing phase 1/1b (BGB-11417-101)

Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer

Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-A3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and in vivo antitumor activity in preclinical models BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumor Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK-V416L resistance in B cell lymphoma models iPSC-derived γδT with novel combinatorial knockout demonstrated significant anti-tumor activity and extended longevity without cytokine support

A first-in-human phase 1a/b study of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors and MTAP deficiency Anti-CCR8 mediates long-lasting antitumor immunological memory and enhances anti-tumor immunity in immune-cold cancer through the combination with chemotherapy BG-C477, a novel topoisomerase 1 inhibitor-based ADC, exhibits antitumor activity in carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing preclinical models BGB-B2033, a novel 4-1BB/GPC3 bispecific antibody, exhibits potent in vitro and vivo antitumor activity in preclinical model BGB-C354, a novel B7H3 ADC with high DAR stability and strong bystander effect, demonstrates robust antitumor activity in preclinical models BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model BGBA3055, an afucosylated anti-CCR8 antibody, preferentially depletes intratumoral regulatory T cells and inhibits tumor growth in preclinical models BTK T474I with enhanced kinase activity confers growth advantage over BTK-L528W with kinase deficiency in B malignant cells Deep plasma proteome profiling to discover drug treatment related novel biomarkers in non-small cell lung cancer EGFR x MET tsAb: differentiated MET biparatopic design with optimal MET inhibitory activity to pursue best-in-class opportunity Integrative spatial and single-cell analysis elucidates tumor microenvironment heterogeneity in NSCLC Preclinical characterization of BGB-B3227, a MUC1 x CD16A bispecific engager, for the treatment of MUC1-expressing solid tumors: Preclinical evaluation of BG-C137, a potential first-in-class FGFR2b targeting ADC, for the treatment of FGFR2b-expressing cancer Single-cell gene expression profiling of the tumor immune microenvironment (TIME) and its association with immunotherapy response in syngeneic mouse models Zanubrutinib (zanu) overcomes BTK V416L resistance in B cell lymphoma models iPSC-derived gdT with novel combinatorial KO demonstrated significant anti-tumor activity and extended longevity without cytokine support

L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Analyse comparative d’efficacité de zanubrutinib plus obinutuzumab dans le lymphome folliculaire en rechute/réfractaire : Growth Modulation Index (GMI) dans l'étude ROSEWOOD Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: Growth modulation index analysis from ROSEWOOD study Le zanubrutinib a démontré une tolérance et une efficacité chez les patients intolérants à l’acalabrutinib traités pour des néoplasies lymphoïdes B L’association sonrotoclax et zanubrutinib permet des taux élevés de clairance de la maladie résiduelle avec une tolérance satisfaisante en première ligne de leucémie lymphoïde chronique : données de l’étude de phase 1/1b en cours BGB-11417-101 Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenström macroglobulinemia: results from the phase 1 CaDAnCe-101 study Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study Real-world Bruton tyrosine kinase inhibitor treatment patterns and outcomes among patients with CLL/SLL in US community oncology practices Résultats d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton BGB-16673 chez les patients atteints de leucémie lymphoïde chronique/lymphome lymphocytique en rechute et/ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Résultats préliminaires d’efficacité et de tolérance du dégradeur de la tyrosine kinase de Bruton (BTK) BGB-16673 chez les patients atteints de macroglobulinémie de Waldenström (MW) en rechute ou réfractaire : résultats de l’étude de phase 1 CaDAnCe-101 Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101 Utilisation des inhibiteurs de tyrosine kinase de Bruton (iBTK) en vie réelle et résultats cliniques chez les patients atteints d’une leucémie lymphoïde chronique (LLC) ou d’un lymphome lymphocytique (LL) Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies

Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase 1/1b study BGB-11417-101

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer (supplement)

Tislelizumab (TIS) combined with chemotherapy (CT) as first-line (1L) therapy for locally advanced or metastatic non-squamous non-small cell lung cancer (LA/M nsq-NSCLC): programmed death-ligand 1 (PD-L1) expression ≥50% subgroup analysis of the randomized, phase 3 RATIONALE-304 trial Transportability of RATIONALE-315 trial outcomes to the European patient population in resectable non-small cell lung cancer

Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l'adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JOG/CG) avancé ou métastatique sans surexpression HER2 (HER2-négatif): Étude RATIONALE-305 – Actualisation après 36 mois de suivi Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l’adénocarcinome gastrique ou de la jonction gastro-œsophagienne (AG/JGO), avancé ou métastatique, HER2-négatif: analyse des résultats de l’étude RATIONALE-305 selon différents scores d’expression de PD-L1 Étude RATIONALE-306 comparant le Tislélizumab (TIS) + chimiothérapie (CT) versus placebo (PBO) + CT dans le carcinome épidermoïde de l’œsophage (CEO) avancé ou métastatique : analyse des résultats selon différents scores d’expression de PD-L1 Étude internationale de phase 3 évaluant tislélizumab + chimiothérapie (CT) par rapport à un placebo + CT en première ligne de traitement du carcinome épidermoïde de l’œsophage avancé/métastatique: analyse de survie de RATIONALE-306 après 3 ans de suivi

Global, randomized, phase 3 study of tislelizumab + chemotherapy versus placebo + chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): minimum 3-year survival follow-up Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): programmed death-ligand 1 (PD-L1) biomarker analysis from the RATIONALE-306 study Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Programmed death-ligand 1 (PD-L1) biomarker analysis from RATIONALE-305 study Tislelizumab (TIS) + chemotherapy (CT) versus placebo (PBO) + CT in human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l'adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JOG/CG) avancé ou métastatique sans surexpression HER2 (HER2-négatif): Étude RATIONALE-305 – Actualisation après 36 mois de suivi Tislélizumab + chimiothérapie (CT) versus placebo + CT dans l’adénocarcinome gastrique ou de la jonction gastro-œsophagienne (AG/JGO), avancé ou métastatique, HER2-négatif: analyse des résultats de l’étude RATIONALE-305 selon différents scores d’expression de PD-L1 Étude RATIONALE-306 comparant le Tislélizumab (TIS) + chimiothérapie (CT) versus placebo (PBO) + CT dans le carcinome épidermoïde de l’œsophage (CEO) avancé ou métastatique : analyse des résultats selon différents scores d’expression de PD-L1 Étude internationale de phase 3 évaluant tislélizumab + chimiothérapie (CT) par rapport à un placebo + CT en première ligne de traitement du carcinome épidermoïde de l’œsophage avancé/métastatique: analyse de survie de RATIONALE-306 après 3 ans de suivi